Pharmacology in the Era of Intervention

2026 | Volume 2 | Issue 1 | Page 84-88

Dr. Abhimita Singh, Professor, Cardiology, JMCH, Jalgwao, MP

Abstract

Pharmacology in the Era of Intervention.

Download • 371KB

While mechanical and robotic innovations have redefined the physical landscape of the catheterization lab, the success of these procedures remains inextricably linked to advanced Pharmacotherapy. The "NextGen" era of intervention is not just about the hardware of stents and valves, but the biological management of the blood-surface interface. This chapter evaluates the evolving role of pharmacology in the era of intervention, focusing on the transition from broad-spectrum anticoagulation to Precision Antiplatelet Therapy. We examine the clinical shift toward P2Y12 Inhibitor Monotherapy, moving away from long-term Dual Antiplatelet Therapy (DAPT) to reduce bleeding complications without sacrificing ischemic protection. A primary focus is placed on the use of Cangrel or, a high-potency intravenous P2Y12 inhibitor that provides "instant-on, instant-off" platelet inhibition during complex CHIP and TAVR procedures. Furthermore, the chapter discusses the integration of Potent Lipid-Lowering Therapies, specifically PCSK9 Inhibitors and Inclisiran, which are now initiated in the acute phase of myocardial infarction to stabilize plaques at the molecular level. By synthesizing data from 2024–2026 trials such as STOPDAPT-3 and EVOLVE-MI, this chapter illustrates how "Interventional Pharmacology" acts as the chemical scaffold that prevents stent thrombosis and periprocedural stroke. As we look toward 2030, the synergy between pharmacology and intervention signifies a move toward "Personalized Hemostasis," where a patient’s genetic profile dictates their specific antithrombotic cocktail